Association of varying number of doses of quadrivalent human papillomavirus vaccine with incidence of condyloma.

Eva Herweijer, Amy Leval, Alexander Ploner, Sandra Eloranta, Julia Fridman Simard, Joakim Dillner, Eva Netterlid, Pär Sparén, Lisen Arnheim-Dahlström

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskriftPeer review

Sammanfattning

Determining vaccine dose-level protection is essential to minimize program costs and increase mass vaccination program feasibility. Currently, a 3-dose vaccination schedule is recommended for both the quadrivalent and bivalent human papillomavirus (HPV) vaccines. Although the primary goal of HPV vaccination programs is to prevent cervical cancer, condyloma related to HPV types 6 and 11 is also prevented with the quadrivalent vaccine and represents the earliest measurable preventable disease outcome for the HPV vaccine.
Originalspråkengelska
Sidor (från-till)597-603
TidskriftJAMA: The Journal of the American Medical Association
Volym311
Nummer6
DOI
StatusPublished - 2014

Ämnesklassifikation (UKÄ)

  • Arbetsmedicin och miljömedicin
  • Dermatologi och venereologi

Fingeravtryck

Utforska forskningsämnen för ”Association of varying number of doses of quadrivalent human papillomavirus vaccine with incidence of condyloma.”. Tillsammans bildar de ett unikt fingeravtryck.

Citera det här